IDH2 and acute myeloid leukemia: Correlative studies have been carried out on samples derived from the patients enrolled in this large clinical trial on mutant IDH2 AML patients and several observations have been made helping to better understand the mechanisms through which enasidenib exerts its antileukemic effects [123,147].